Alessandro Cannavo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1891917/publications.pdf

Version: 2024-02-01

65 papers	2,218 citations	172207 29 h-index	233125 45 g-index
70 all docs	70 docs citations	70 times ranked	3015 citing authors

#	Article	IF	Citations
1	Periodontal Disease: A Risk Factor for Diabetes and Cardiovascular Disease. International Journal of Molecular Sciences, 2019, 20, 1414.	1.8	229
2	Negative Impact of Î²-Arrestin-1 on Post-Myocardial Infarction Heart Failure via Cardiac and Adrenal-Dependent Neurohormonal Mechanisms. Hypertension, 2014, 63, 404-412.	1.3	102
3	Targeting cardiac Î²-adrenergic signaling via GRK2 inhibition for heart failure therapy. Frontiers in Physiology, 2013, 4, 264.	1.3	95
4	Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System. Frontiers in Pharmacology, 2017, 8, 556.	1.6	80
5	microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases. Frontiers in Medicine, 2017, 4, 74.	1.2	80
6	Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic Denervation in Patients With Heart Failure. Circulation Research, 2016, 118, 1244-1253.	2.0	74
7	Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. European Journal of Preventive Cardiology, 2014, 21, 4-11.	0.8	71
8	Î² ₁ -Adrenergic Receptor and Sphingosine-1-Phosphate Receptor 1 (S1PR1) Reciprocal Downregulation Influences Cardiac Hypertrophic Response and Progression to Heart Failure. Circulation, 2013, 128, 1612-1622.	1.6	69
9	EGFR trans-activation by urotensin II receptor is mediated by Î²-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Research in Cardiology, 2011, 106, 577-589.	2.5	68
10	Targeting Î²3-Adrenergic Receptors in the Heart: Selective Agonism and Î²-Blockade. Journal of Cardiovascular Pharmacology, 2017, 69, 71-78.	0.8	67
11	GRK2 blockade with Î²ARKct is essential for cardiac Î²2-adrenergic receptor signaling towards increased contractility. Cell Communication and Signaling, 2013, 11, 64.	2.7	63
12	Blockade of Î²â€adrenoceptors restores the GRK2â€mediated adrenal Î±₂â€adrenoceptorâ€“catecholamine production axis in heart failure. British Journal of Pharmacology, 2012, 166, 2430-2440.	2.7	59
13	Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases. Nature Communications, 2016, 7, 10877.	5.8	56
14	GRK2 as a therapeutic target for heart failure. Expert Opinion on Therapeutic Targets, 2018, 22, 75-83.	1.5	56
15	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 3793-3807.	2.9	53
16	GRK2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levels. Journal of Molecular and Cellular Cardiology, 2015, 89, 360-364.	0.9	51
17	Genetic Deletion of Uncoupling Protein 3 Exaggerates Apoptotic Cell Death in the Ischemic Heart Leading to Heart Failure. Journal of the American Heart Association, 2013, 2, e000086.	1.6	50
18	Vascular Endothelial Growth Factor Blockade Prevents the Beneficial Effects of Î²-Blocker Therapy on Cardiac Function, Angiogenesis, and Remodeling in Heart Failure. Circulation: Heart Failure, 2013, 6, 1259-1267.	1.6	49

#	Article	IF	Citations
19	Potential Bidirectional Relationship Between Periodontitis and Alzheimerâ€™s Disease. Frontiers in Physiology, 2020, 11, 683.	1.3	49
20	Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	1.9	46
21	Chronic Î²1-adrenergic blockade enhances myocardial Î²3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective Î²1-blocker therapy. Basic Research in Cardiology, 2015, 110, 456.	2.5	43
22	Identification and Characterization of Amlexanox as a G Protein-Coupled Receptor Kinase 5 Inhibitor. Molecules, 2014, 19, 16937-16949.	1.7	42
23	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine. Journal of Medicinal Chemistry, 2017, 60, 3052-3069.	2.9	41
24	Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally Designed Inhibitor. Journal of Biological Chemistry, 2015, 290, 20649-20659.	1.6	39
25	Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart Failure. Circulation Research, 2016, 118, 1116-1124.	2.0	38
26	Î² 1 -Blockade Prevents Post-Ischemic Myocardial Decompensation Via Î² 3 AR-Dependent Protective Sphingosine-1 Phosphate Signaling. Journal of the American College of Cardiology, 2017, 70, 182-192.	1.2	37
27	Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families. Clinical Genetics, 2011, 79, 438-447.	1.0	34
28	Infective Endocarditis: A Focus on Oral Microbiota. Microorganisms, 2021, 9, 1218.	1.6	34
29	Impact of aging on cardiac sympathetic innervation measured by 123I-mIBG imaging in patients with systolic heart failure. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2392-2400.	3.3	33
30	Molecular aspects of the cardioprotective effect of exercise in the elderly. Aging Clinical and Experimental Research, 2013, 25, 487-497.	1.4	31
31	Î²-Adrenergic Receptors and G Protein-Coupled Receptor Kinase-2 in Alzheimer's Disease: A New Paradigm for Prognosis and Therapy?. Journal of Alzheimer's Disease, 2013, 34, 341-347.	1.2	31
32	Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1252-1261.	2.2	30
33	Differential Role of G Proteinâ€“Coupled Receptor Kinase 5 in Physiological Versus Pathological Cardiac Hypertrophy. Circulation Research, 2015, 117, 1001-1012.	2.0	27
34	Structural Determinants Influencing the Potency and Selectivity of Indazole-Paroxetine Hybrid G Proteinâ€“Coupled Receptor Kinase 2 Inhibitors. Molecular Pharmacology, 2017, 92, 707-717.	1.0	27
35	Atrial fibrillation in the elderly: a risk factor beyond stroke. Ageing Research Reviews, 2020, 61, 101092.	5.0	26
36	Impact of diabetes mellitus on lymphocyte <scp>GRK</scp>2 protein levels in patients with heart failure. European Journal of Clinical Investigation, 2015, 45, 187-195.	1.7	25

#	Article	IF	Citations
37	Induction of Mitogen-Activated Protein Kinases Is Proportional to the Amount of Pressure Overload. Hypertension, 2010, 55, 137-143.	1.3	24
38	Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity. Aging Clinical and Experimental Research, 2019, 31, 321-330.	1.4	18
39	Risk of acute myocardial infarction after transurethral resection of prostate in elderly. BMC Surgery, 2013, 13, S35.	0.6	15
40	Changes of plasma norepinephrine and serum N-terminal pro-brain natriuretic peptide after exercise training predict survival in patients with heart failure. International Journal of Cardiology, 2014, 171, 384-389.	0.8	15
41	GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease. Cellular Signalling, 2018, 41, 33-40.	1.7	15
42	Aldosterone Jeopardizes Myocardial Insulin and Î²-Adrenergic Receptor Signaling via G Protein-Coupled Receptor Kinase 2. Frontiers in Pharmacology, 2019, 10, 888.	1.6	14
43	Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?. Cells, 2021, 10, 457.	1.8	14
44	Â Adrenergic Receptor Kinase C-Terminal Peptide Gene-Therapy Improves Â2-Adrenergic Receptor-Dependent Neoangiogenesis after Hindlimb Ischemia. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 503-513.	1.3	13
45	Alteration of myocardial GRK2 produces a global metabolic phenotype. JCI Insight, 2019, 4, .	2.3	13
46	Targeting GRK5 for Treating Chronic Degenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 1920.	1.8	12
47	GRK2 Regulates Î±2-Adrenergic Receptorâ€“Dependent Catecholamine Release in Human Adrenal Chromaffin Cells. Journal of the American College of Cardiology, 2017, 69, 1515-1517.	1.2	11
48	Sex Differences in Cardiovascular Diseases: A Matter of Estrogens, Ceramides, and Sphingosine 1-Phosphate. International Journal of Molecular Sciences, 2022, 23, 4009.	1.8	10
49	Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19. Minerva Endocrinology, 2022, 47, .	0.6	8
50	Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium. Expert Review of Cardiovascular Therapy, 2013, 11, 999-1013.	0.6	7
51	Aldosterone and Myocardial Pathology. Vitamins and Hormones, 2019, 109, 387-406.	0.7	6
52	Genetic Catalytic Inactivation of GRK5 Impairs Cardiac Function in Mice Via Dysregulated P53 Levels. JACC Basic To Translational Science, 2022, 7, 366-380.	1.9	6
53	Eating Away at Heart Failureâ^—. Journal of the American College of Cardiology, 2015, 66, 2534-2535.	1.2	2
54	G Protein-Coupled Receptor and Their Kinases in Cell Biology and Disease. International Journal of Molecular Sciences, 2022, 23, 5501.	1.8	2

#	Article	IF	Citations
55	Is the Hitman in Cardiac Death HiddenÂinÂthe SympatheticÂNervousÂSystem Remodeling?. Journal of the American College of Cardiology, 2020, 75, 14-16.	1.2	1
56	Aging is associated with cardiac autonomic nerve fiber depletion and reduced cardiac and circulating BDNF levels. Journal of Geriatric Cardiology, 2021, 18, 549-559.	0.2	1
57	G-Protein-Coupled Receptors and Their Kinases in Cardiac Regulation. Methods in Pharmacology and Toxicology, 2016, , 271-281.	0.1	0
58	Burning Redoxstats in the Brainstem. Hypertension, 2017, 69, 1019-1021.	1.3	0
59	GRK5â€Ðependent p53 Activity Controls Basal Cardiac Function and Survival. FASEB Journal, 2021, 35, .	0.2	0
60	Editorial: Molecular Mechanisms Involved in Heart Failure, Parkinsonâ€™s, and Alzheimerâ€™s Diseases. Frontiers in Molecular Biosciences, 2021, 8, 754987.	1.6	0
61	Abstract 13888: Long-term Intermittent Fasting Treatment Improves Cardiac Function and Inotropic Reserve by Restoration of Cardiac Beta-adrenergic Signaling in an Experimental Model of Chronic Heart Failure. Circulation, 2014, 130, .	1.6	0
62	The Adrenergic System of the Myocardium. , 2015, , 13-24.		0
63	Abstract 340: Myocyte-borne Bdnf is Essential to Limit Post-ischemic Cardiac Injury and Dysfunction. Circulation Research, 2020, 127, .	2.0	0
64	Abstract P426: Inactivating Grk5 Impairs Basal Cardiac Function And Survival Via P53 Modulation. Circulation Research, 2021, 129, .	2.0	0
65	Abstract P358: Cardiac Innervation Remodeling And Impaired Brain Derived Neurotrophic Factor (bdnf) Levels In Physiological Aging Vivo Model. Circulation Research, 2021, 129, .	2.0	0